Global Eosinophilic Esophagitis Market Insights Forecasts to 2030

• The global eosinophilic esophagitis market was valued at USD 138.4 million in 2021.
• The market is growing at a CAGR of 34% from 2021 to 2030
• The global eosinophilic esophagitis market is expected to reach USD 1,927 million by 2030
• The Asia-Pacific is expected to grow the fastest during the forecast period

The global eosinophilic esophagitis market is expected to reach USD 1,927 million by 2030, at a CAGR of 34% during the forecast period 2022 to 2030. This industry is growing because there are more people with rare diseases around the world and the market is growing. White blood cell-related autoimmune diseases are becoming more common, which is driving the market for diseases caused by eosinophils.

 Market Overview:

EoE, or eosinophilic esophagitis, is a disease of the oesophagus that lasts for a long time. It is caused by the immune system. People with EoE have an abnormally high number of white blood cells called eosinophils in the lining of their oesophagus. This buildup, which can be caused by a reaction to food, an allergy, or acid reflux, can make the oesophagus hurt or inflamed. Adults with eosinophilic esophagitis have trouble swallowing, a blockage, chest pain that is often in the middle and doesn't go away with antacids, and food that hasn't been digested coming back up. It's likely that the growth of the market would be caused by people learning more about the diseases caused by eosinophils. For example, the American Partnership for Eosinophilic Disorders (APFED) has been working on this project with the help of major pharmaceutical companies like AstraZeneca plc, Sanofi S.A., Bristol Myers Squibb, Arena Pharmaceuticals, Inc., and others that support APFED in order to organise National Eosinophil Awareness Week (NEAW). The market gets bigger because of this. Eosinophil-driven diseases like eosinophilic esophagitis are now being treated with a number of therapeutic candidates that are being developed and researched very successfully. In clinical studies, these potential drugs have done well, which is good news. Because of this, regulatory agencies like the Food and Drug Administration in the United States are given names for these potential drugs. For example, Ellodi Pharmaceuticals, a specialty pharmaceutical company that focuses on gastroenterology, announced in February 2021 that it had received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE). This rare form of eosinophilic esophagitis is characterised by eosinophilic infiltration of the oesophagus. This is a type of persistent allergic inflammation. This is another thing that is expected to drive growth in the leukotriene inhibitors market.

Report Coverage

This research report categorizes the market for global based eosinophilic esophagitis market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global eosinophilic esophagitis market. Recent market developments and competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each global eosinophilic esophagitis market sub-segments.

Segmentation Analysis

• In 2021, the proton pump inhibitor segment dominated the market with the largest market share of 35% and market revenue of 48.44 million.

Based on the drug class, the eosinophilic esophagitis market is categorized Corticosteroids (Budesonide (Jorveza, Off-label budesonide), Fluticasone), Proton Pump Inhibitor (PPI) (Omeprazole, Esomeprazole, Others), and Late Stage Pipeline Drugs (Dupixent, APT-1011, Lirentelimab (AK002), Cendakimab, Etrasimod, TAK-721, Omilancor (BT-11) . In 2021, the proton pump inhibitor segment dominated the market with the largest market share of 35% and market revenue of 48.44 million. Proton-pump inhibitors (PPIs), which are a group of drugs, cause the stomach to make much less acid. This effect lasts for a long time. They do this by stopping the stomach's H+/K+ ATPase proton pump in a way that can't be undone. They are the most powerful acid-secretion-blocking medicines that can be bought right now.

In 2021, the hospital pharmacies segment accounted for the largest share of the market, with 40% and market revenue of 55.36 million.

Based on the distribution channel, the eosinophilic esophagitis market is categorized into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. In 2021, hospital pharmacies dominated the market with the largest market share of 40% and market revenue of 55.36 million. The hospital pharmacies is increasing because of the increased drugs sale for eosinophilic esophagitis.

Regional Segment Analysis of the Eosinophilic Esophagitis Market

• North America (U.S., Canada, Mexico)
• Europe (Germany, France, the U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America)
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

Among all regions, North America emerged as the largest market for the global eosinophilic esophagitis market, with a market share of around 38% and 138.4 million of the market revenue in 2021.

• In 2021, North America emerged as the largest market for the global eosinophilic esophagitis market, with a market share of around 38% and 138.4 million of the market revenue. In the past few years, the growth of the regional market has been helped by a good economy and the rise of a number of domestic manufacturers with good technical skills and lower prices than those in Europe and North America, where economies are more developed.
• The Asia-Pacific market is expected to grow at the fastest CAGR between 2022 and 2030. Due to growing healthcare facilities, a high number of the generic manufacturer, and a rise in government efforts and specialised communities, Asia-Pacific has been experiencing a good expansion for the worldwide eosinophil-driven illnesses market during the forecast period.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global eosinophilic esophagitis market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Market Players:

• Takeda Pharmaceutical Company Limited (Japan)
• Ellodi Pharmaceuticals (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• AstraZeneca (U.K.)
• GSK plc(U.S.)
• Regeneron Pharmaceuticals Inc. (U.S.)
• Allakos Inc (U.S.)
• Arena Pharmaceuticals Ltd (U.S.)
• Revolo Biotherapeutics (U.S.)
• DBV Technologies (France)
• Cipla Inc (India)
• Sun Pharmaceutical Industries Ltd (India)
• Sanofi (France)

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities
• Consulting And Research Firm
• Venture capitalists
• Third-party knowledge providers
• Value-Added Resellers (VARs)

Recent Development

• In January 2020, it came out that Fasenra would be taking part in three clinical studies for skin disorders caused by eosinophils. Here, two Phase II studies and one Phase III study are being done to see how well the drug works for treating atopic dermatitis (AD) and chronic spontaneous urticaria (CSU), respectively.
• In April 2022, Escorten was put on the Korean market by Daewon Pharmaceutical. This was one of the first proton-pump inhibitors that could be bought in the United States. There is an esomeprazole magnesium trihydrate dose of 10 milligrammes that can be taken.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2021 to 2030. Spherical Insights has segmented the global eosinophilic esophagitis market based on the below-mentioned segments:

Global Eosinophilic Esophagitis Market, By Drug Class

• Corticosteroids (Budesonide (Jorveza, Off-label budesonide), Fluticasone)
• Proton Pump Inhibitor (PPI) (Omeprazole, Esomeprazole, Others)
• Late Stage Pipeline Drugs (Dupixent, APT-1011, Lirentelimab (AK002), Cendakimab, Etrasimod, TAK-721, Omilancor (BT-11)

Global Eosinophilic Esophagitis Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Eosinophilic Esophagitis Market, Regional Analysis

• North America
  • THE US
  • Canada
  • Mexico
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• The Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa